Despite the advances of new and innovative drugs, the prognosis of patients suffering from metastasized kidney cancer is still poor. The underlying mechanism of the heterogeneous responses to approved immune checkpoint inhibitors remains unclear. Using one of the first autochthonous mouse models of clear cell renal cell carcinoma we want to investigate the impact of the transcription factors HIF-1α and HIF-2α on the tumor microenvironment. We thereby want to identify new pharmacological targets and establish novel predictive and prognostic biomarkers.

Here you can get further information.